Panmira appoints chief executive
Hari Kumar will oversee inflammation portfolio
Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.
Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.
Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.
The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.
You may also like
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster